Device Trial Radar · NCT06578741
GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
310
Actual
Start
Nov 25, 2024
Primary completion
Jun 25, 2027
Study completion Jun 1, 2036
Sponsor
- Lead sponsor
- W.L.Gore & AssociatesNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 29, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.
Conditions
- Abdominal Aortic Aneurysm
- Pararenal Aortic Aneurysm
- Thoracoabdominal Aortic Aneurysm
Interventions
GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)Device
Treatment with the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) in patients with Pararenal Abdominal Aortic Aneurysms and Thoracoabdominal Aortic Aneurysms
Primary outcomes
What the sponsor says the trial is designed to measure.
- Co-Primary Endpoint #1: Technical SuccessTime frame: Time of index procedure
- Co-Primary Endpoint #2: Clinical SuccessTime frame: Index procedure through 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford Hospital
Stanford, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.